Clinical Trials Browser

Phase 3 × Papillomavirus Infections × Gynecologic × Clear all

Squamous Intraepithelial Lesions, Acquired Immunodeficiency Syndrome, Anus Neoplasms, HIV Infections, Papillomavirus Infections

NCT04895020 2024-04-17

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Phase 3 Recruiting

1,200 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05027776 2024-04-17

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Phase 3 Recruiting

1,348 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Papillomavirus Infections

NCT05372016 2023-11-24

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Completed

1,200 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Phase 3 Active not recruiting

2,750 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05580341 2022-10-28

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Phase 3 Unknown

1,200 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT00943722 2022-10-03

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

Phase 3 Completed

3,074 enrolled 24 charts

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00947115 2020-10-30

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

Phase 3 Completed

525 enrolled 24 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01164722 2020-08-04

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

Phase 3 Completed

120 enrolled 13 charts

GastrointestinalGynecologicOther neoplasm

Squamous Intraepithelial Lesions, Anus Neoplasms, Precancerous Conditions, HIV Infections, Papillomavirus Infections

NCT01381575 2020-06-09

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Phase 3 Completed

1,447 enrolled 26 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT03546842 2020-02-25

V503-017

Phase 3 Completed

201 enrolled 11 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections, Adenocarcinoma in Situ

NCT00877877 2020-01-18

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.

Phase 3 Completed

632 enrolled 28 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Phase 3 Completed

152 enrolled 21 charts

Gynecologic

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00294047 2020-01-02

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Phase 3 Completed

5,752 enrolled 42 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00423046 2020-01-02

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Phase 3 Completed

1,106 enrolled 27 charts

Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT03158220 2019-11-21

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Phase 3 Completed

1,212 enrolled 15 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT01190176 2019-10-30

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Phase 3 Completed

34 enrolled 12 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00937950 2019-10-29

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Phase 3 Completed

2,022 enrolled 10 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00779766 2019-06-10

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Phase 3 Completed

6,081 enrolled 26 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01254643 2018-11-28

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Phase 3 Completed

100 enrolled 8 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00543543 2018-11-27

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Phase 3 Completed

14,840 enrolled 21 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT01245764 2018-11-14

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Phase 3 Completed

250 enrolled 20 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT02346227 2018-10-12

KINVAV

Phase 3 Completed

327 enrolled

Gynecologic

Uterine Cervical Dysplasia, Infections, Papillomavirus Infections

NCT00492544 2018-09-04

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Phase 3 Completed

100 enrolled 9 charts

Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00578227 2018-08-17

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

814 enrolled 28 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00652938 2018-08-17

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

744 enrolled 27 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00345878 2018-07-20

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Phase 3 Completed

271 enrolled 12 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00485732 2018-07-20

A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

Phase 3 Completed

225 enrolled 14 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00799825 2018-07-12

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Phase 3 Completed

346 enrolled 8 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00552279 2018-06-25

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

Phase 3 Completed

805 enrolled 16 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00973362 2017-01-06

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

Phase 3 Completed

12,896 enrolled 11 charts

Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Papillomavirus Infections, Atypical Squamous Cells of the Cervix

NCT00306241 2016-11-04

A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Phase 3 Completed

300 enrolled

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00929526 2016-10-20

Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study

Phase 3 Completed

752 enrolled 21 charts

Gynecologic

Uterine Cervical Dysplasia, Papillomavirus Infections

NCT00849381 2014-09-12

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand

Phase 3 Completed

1,239 enrolled 9 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00316706 2012-09-18

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Phase 3 Completed

1,245 enrolled 11 charts

Gynecologic

Uterine Cervical Dysplasia, Papillomavirus Infections

Clinical Trials

ANCHOR

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

V503-017

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

KINVAV

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine